Ocular Therapeut (OCUL) Stock Price, Quote & News

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 357 4000

Fax: 781 275 7562

Website: www.ocutx.com

Address:

15 Crosby Drive, Bedford, United States

Vanderm98 Dec. 4 at 11:21 PM

$OCUL Very encouraging we picked up this green volume with a MC of $2.5b. I was pretty sure it was petered out for a while. Big tute thinks there’s value here. GL

0 · Reply

Iightning Dec. 4 at 10:15 PM

1ightning® Premium Options Alert (Actionable) Ticker: $OCUL Contract: Dec 19 $12.5C Entry: 0.75 Exit: 1.16 Return: +55.31% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

dixiebull Dec. 4 at 9:55 PM

$OCUL got to 13, so now we want 12.50 to break for 13 and 13.50 $SANA ran to 5.49, see if 5 holds for 5.50 and 6 $DGXX made it to 3.83, if that 4 can break it can get 4.50/5 $USAR beast today to 17.73, if momo keep sin it can get 18 to 20 $SERV made my 13 target from watchlist so ow we want 12.50 to hold on a dip for 13 to 13.50/14

0 · Reply

ShortSuckieTuckie Dec. 4 at 9:37 PM

$OCUL This sharp rebound with volume off of what was once the resistance line is a very bullish indication. I will not be surprised if this now moves up to the $15 area.

2 · Reply

Fishfearme72 Dec. 4 at 6:55 PM

$OCUL Another move up on thin air. EYPT up over $2.. seen this before, just wondering when OCUL will go up on its own merit???

1 · Reply

SmokenTuna Dec. 4 at 4:37 PM

$OCUL our competition is flying too!! Strange..

0 · Reply

KYLE0829 Dec. 4 at 4:29 PM

$OCUL hahaha Sawicki you are not very smart. Only an emotional person would say dont be emotional. I merley said you are wrong very often and today proves my point. How is $7-$8 going? You should stop posting now.

1 · Reply

SmokenTuna Dec. 4 at 4:23 PM

$OCUL I spoke to soon! lol I’ll eat some humble pie if we break 15.

1 · Reply

fsu45 Dec. 4 at 3:46 PM

$OCUL What the ??

1 · Reply

Mmmm888 Dec. 4 at 3:41 PM

$OCUL Time for some portfolio porn

0 · Reply

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:05 AM EST - 4 weeks ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:00 AM EST - 4 weeks ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Oct 7, 2025, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Oct 1, 2025, 4:22 AM EDT - 2 months ago

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Sep 30, 2025, 7:08 AM EDT - 2 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 6:21 AM EDT - 2 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 8, 2025, 5:05 PM EDT - 3 months ago

Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 7, 2025, 1:52 AM EDT - 3 months ago

Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care

Aug 5, 2025, 9:12 PM EDT - 4 months ago

OCUL Sales Drop 18%

Aug 5, 2025, 1:33 PM EDT - 4 months ago

Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript

Jun 26, 2025, 1:54 PM EDT - 5 months ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 16, 2025, 7:00 AM EDT - 6 months ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

May 14, 2025, 7:00 AM EDT - 7 months ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Apr 11, 2025, 4:30 PM EDT - 8 months ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 14, 2025, 8:36 AM EDT - 9 months ago

Why Ocular Therapeutix Was Bumping Higher This Week

Mar 11, 2025, 2:49 PM EDT - 9 months ago

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Mar 6, 2025, 11:15 AM EST - 9 months ago

Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Mar 3, 2025, 10:16 AM EST - 9 months ago

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 7:00 AM EST - 10 months ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 3, 2025, 7:00 AM EST - 10 months ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Jan 14, 2025, 7:00 AM EST - 11 months ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Dec 30, 2024, 12:16 PM EST - 1 year ago

Ocular Is Now Thoroughly Derisked

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 14, 2024, 10:34 AM EST - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 11, 2024, 5:50 AM EDT - 1 year ago

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

AMD

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Aug 9, 2024, 12:53 PM EDT - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Jul 31, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jun 20, 2024, 9:13 AM EDT - 1 year ago

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

SWKS BFH IRTC TRU

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 4, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 3, 2024, 2:01 PM EDT - 1 year ago

Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough

Jun 1, 2024, 5:30 AM EDT - 1 year ago

Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 6, 2024, 8:16 PM EDT - 1 year ago

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vanderm98 Dec. 4 at 11:21 PM

$OCUL Very encouraging we picked up this green volume with a MC of $2.5b. I was pretty sure it was petered out for a while. Big tute thinks there’s value here. GL

0 · Reply

Iightning Dec. 4 at 10:15 PM

1ightning® Premium Options Alert (Actionable) Ticker: $OCUL Contract: Dec 19 $12.5C Entry: 0.75 Exit: 1.16 Return: +55.31% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

dixiebull Dec. 4 at 9:55 PM

0 · Reply

ShortSuckieTuckie Dec. 4 at 9:37 PM

$OCUL This sharp rebound with volume off of what was once the resistance line is a very bullish indication. I will not be surprised if this now moves up to the $15 area.

2 · Reply

Fishfearme72 Dec. 4 at 6:55 PM

$OCUL Another move up on thin air. EYPT up over $2.. seen this before, just wondering when OCUL will go up on its own merit???

1 · Reply

SmokenTuna Dec. 4 at 4:37 PM

$OCUL our competition is flying too!! Strange..

0 · Reply

KYLE0829 Dec. 4 at 4:29 PM

1 · Reply

SmokenTuna Dec. 4 at 4:23 PM

$OCUL I spoke to soon! lol I’ll eat some humble pie if we break 15.

1 · Reply

fsu45 Dec. 4 at 3:46 PM

$OCUL What the ??

1 · Reply

Mmmm888 Dec. 4 at 3:41 PM

$OCUL Time for some portfolio porn

0 · Reply

Fairvalue10 Dec. 4 at 3:22 PM

$OCUL Comments ... we had nothing new with a recorded message not even live with no support.... Well I take it 😀

2 · Reply

Vanderm98 Dec. 4 at 3:21 PM

$OCUL This is what it looks like when something is happening. GL

0 · Reply

Jjarnold44 Dec. 4 at 3:15 PM

$OCUL Apparently the market has digested the comments in a positive light just as we did. Should be $6 -$8 any day now! 😆 🤣 😂 Ho ho ho.

0 · Reply

The_Fudge_ster Dec. 4 at 3:15 PM

$OCUL the fook is going on here today??

1 · Reply

Fairvalue10 Dec. 4 at 3:07 PM

$OCUL Moving with volume

0 · Reply

MoneyGroupLLC Dec. 4 at 1:40 PM

Enter: $OCUL Calls Strike Price: $12 Expiry Date: JAN 16 2026 Buy in Price: $1.08 - $1.25 Sell Price: $1.75 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

HedgeAlerts Dec. 4 at 7:43 AM

Hedge Alert Live - Protect Your Portfolio Contract: $OCUL $11.00 Put · DEC 19, 2025 Exp Entry Price: $0.40 - $0.45 Exit Price Target: $0.54 Profit Margin: +34% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Iightning Dec. 4 at 5:56 AM

1ightning® Premium Options Alert (Actionable) Ticker: $OCUL Contract: Dec 19 $12.5C Entry: 1.07 Exit: 1.93 Return: +79.46% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Dy2ski Dec. 4 at 12:48 AM

$OCUL I appreciated CEO Dugel's comments at today's Piper Conference "But my audience now is just not Clinicians but also Strategics..."

2 · Reply

SmokenTuna Dec. 3 at 6:32 PM

$OCUL there going to keep this stuck until sol1. don’t plan on a run..

5 · Reply

johnj2 Dec. 3 at 5:23 PM

$OCUL first time hearing about IP extension to 2044. Was this announced somewhere?

2 · Reply

Fairvalue10 Dec. 3 at 4:10 PM

$OCUL Live event ...😏

0 · Reply

Market Cap	2.40B
Revenue (ttm)	63.72M
Net Income (ttm)	-193.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-303.69%
Debt to Equity Ratio	0.27

Volume	5,820,300
Avg Vol	2,918,618
Day's Range	N/A - N/A
Shares Out	213.05M
Stochastic %K	22%
Beta	0.96
Analysts	Strong Sell
Price Target	$22.08